Resources

Discover how the UK is accelerating leadership in cell and gene therapies. This new BIA report examines breakthroughs in CGT development, manufacturing efficiency, and patient access—highlighting the innovations, investments, and policy support needed to secure the UK’s position as a global CGT hub.

BIA’s new report reveals how the UK can improve patient access to innovative rare disease medicines and strengthen its position as a global leader.

Our third quarter of has been focused on cementing and building upon our influence achieved in the key government policy documents that were published just before summer, such as the industrial Strategy and Life Sciences Sector Plan. Read on for a full breakdown of what they have been doing on your behalf.

This quarter has seen a cascade of government policy announcements, including the Spending Review and Industrial Strategy. Our team have been rigorously scrutinising and gearing up for the launch of the Life Sciences Sector Plan and the NHS 10-Year Health Plan, two transformative frameworks that could redefine the future of our sector.

This report from the BIA delves into the strategic importance of functional genomics, highlighting its potential to drive innovation across diverse applications, particularly in healthcare.

The UK has a vibrant ecosystem supporting early-stage life science start-ups, with accelerators helping companies raise significantly larger seed rounds and exit more efficiently. Our report highlights a critical gap: there is an urgent need for further support to help companies grow beyond scale, particularly given current headwinds. Addressing this is essential to sustain the UK’s global competitiveness in life sciences.

In 2035, we envision a UK biotech sector with a stronger long-term capital base supporting both early—and later-stage firms. To make Vision 2035 a reality, we, as a sector, must focus on areas that will have the greatest impact. Read the report to find out what those are!

Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.

This report is the first step in understanding the specific challenges faced by female CEOs and C-suite in biotechnology in the UK – in order to understand best how we can help to enact change and provide relevant support.

Welcome to our new-look quarterly report, where the BIA team share examples of the influence we are delivering for members on government policy and the global life sciences ecosystem.